Gene expression profiling provides a molecular view of how cells and tissues respond to biological state, disease-associated processes, immune activation, environmental exposure, experimental treatment, developmental programs, and cellular stress. IMDNA supports research programs using RT-qPCR and multiplex RT-qPCR to measure investigator-selected RNA targets, validate transcriptomic discoveries, characterize pathway-level responses, and develop focused gene-expression signatures.
Our approach connects biological question → sample strategy → RNA quality → target selection → assay design → normalization → analytical evaluation → quantitative interpretation, with emphasis on transparent experimental design and reproducible molecular measurement.
RNA abundance can change with cell type, tissue composition, biological condition, treatment, timepoint, preanalytical handling, RNA integrity, and analytical workflow. A scientifically useful expression study therefore requires more than measuring Cq values: the experimental system, reference strategy, assay efficiency, controls, biological replicates, and interpretation framework must be considered together.
Quantify selected transcripts associated with defined pathways, phenotypes, biomarkers, or experimentally driven hypotheses.
Compare transcript abundance across experimental groups, conditions, tissues, cell populations, treatment arms, doses, or timepoints.
Evaluate combinations of transcripts that may collectively characterize a biological state or research phenotype rather than relying on a single marker.
Develop focused RT-qPCR assays to independently examine candidate genes emerging from RNA-seq, microarray, or other discovery datasets.
The most useful panel is driven by the biology of the project. IMDNA can develop compact or expanded target sets around investigator-defined pathways and research objectives.
Cytokine, chemokine, interferon, innate/adaptive immune, antigen-presentation, and regulatory programs.
Pro-inflammatory and resolving pathways, leukocyte recruitment, inflammatory signaling, and tissue-response programs.
Cell-cycle regulation, growth signaling, proliferative state, and growth-associated transcriptional responses.
Programmed cell death, survival signaling, stress responses, and cell-fate regulation.
Oxygen-sensing, metabolic adaptation, angiogenic signaling, and hypoxia-responsive transcription.
Reactive-oxygen response, antioxidant defense, redox regulation, and cellular stress pathways.
Damage sensing, checkpoint signaling, repair-associated pathways, genomic-stress responses, and cell-cycle effects.
Extracellular-matrix production, matrix turnover, profibrotic signaling, tissue remodeling, and wound-response biology.
Vascular growth, endothelial activation, vascular remodeling, and angiogenic signaling.
Metabolic adaptation, nutrient utilization, mitochondrial programs, glycolytic responses, and cellular energetics.
T-cell/NK-cell effector programs, cytolytic machinery, activation state, and immune-effector responses.
Transcriptional changes before, during, and after experimental exposure to drugs, biologics, radiation, or combination strategies.
Robust profiling begins before amplification. Sample collection, RNA preservation, extraction, reverse transcription, target design, normalization, controls, and data analysis can each influence the observed expression result.
Gene expression technologies answer different questions. High-throughput transcriptomics can provide broad discovery, while targeted RT-qPCR is particularly useful when a defined set of transcripts must be measured efficiently across focused research studies.
| Approach | Best-Fit Research Role | How IMDNA Can Support |
|---|---|---|
| Single-Target RT-qPCR | Focused quantification of individual genes and assay-level characterization. | Primer/probe design, optimization, analytical evaluation, controls, and normalization strategy. |
| Multiplex RT-qPCR | Simultaneous investigation of multiple predefined targets in streamlined workflows. | Multiplex architecture, fluorophore/channel planning, target balancing, interaction testing, and panel optimization. |
| Targeted Expression Panels | Pathway profiling, biomarker signatures, treatment response, and translational research. | Target selection support, custom panel design, reference-gene strategy, analytical characterization, and research workflow development. |
| RNA-seq / Transcriptomic Discovery | Broad transcriptome exploration and generation of candidate genes/signatures. | IMDNA can use investigator-provided transcriptomic findings to prioritize candidates and develop targeted RT-qPCR confirmation assays. |
| Public Transcriptomic Data | Hypothesis generation, target prioritization, context assessment, and independent comparison. | Public resources such as NCBI GEO can inform candidate selection when datasets appropriately match the biological context. |
Common “housekeeping” genes should not automatically be assumed to be stable. Expression can vary with tissue, cell type, disease state, treatment, and experimental condition. Candidate reference genes should therefore be evaluated within the actual biological system and study design.
Depending on the experiment, controls can help distinguish biological expression changes from technical failure or contamination. Appropriate strategies may include no-template controls, no-RT controls, positive materials, inter-run controls, extraction/process controls, and sample-quality assessments.
The 2025 MIQE 2.0 revision emphasizes transparent reporting, sample handling, assay design and validation, normalization, quality control, detection limits, dynamic range, amplification efficiency, and appropriate quantitative analysis. IMDNA can use these principles as a scientific framework when developing research-focused RT-qPCR workflows.
Document biological source, collection, preservation, storage, extraction, RNA quantity/quality, and relevant preanalytical variables.
Design target-specific primers/probes with attention to transcript identity, isoforms, sequence variation, genomic DNA risk, and non-specific amplification.
Characterize efficiency, usable quantitative range, reproducibility, low-level detection behavior, and assay-specific acceptance criteria.
Select and experimentally evaluate suitable reference genes or alternative normalization approaches rather than assuming universal stability.
Use controls appropriate to the workflow and clearly define how control performance influences data acceptance.
Preserve raw data, document analysis methods, and interpret Cq-derived quantities with attention to amplification efficiency and uncertainty.
RNA-seq can identify broad transcriptional patterns and candidate genes across thousands of transcripts. A focused RT-qPCR workflow can then be developed around biologically relevant candidates to evaluate those transcripts in additional samples, experimental conditions, timepoints, or independent cohorts. This transition should not be treated as automatic “validation”: gene identity, transcript/isoform targeting, biological context, reference strategy, sample handling, assay performance, and statistical design must remain aligned with the research question.
Gene-expression workflows can be developed for diverse research materials when the sample type, RNA quality, extraction method, and assay performance are scientifically evaluated for the intended research application.
Cultured cells, stimulated cells, treatment-response models, immune-cell populations, and investigator-defined cellular systems.
Fresh/frozen tissues and appropriately processed archival materials, including FFPE-derived RNA when assay design and RNA quality are suitable.
Whole blood, PBMCs, isolated cell populations, and other blood-derived research materials with suitable RNA preservation and workflow controls.
Investigator-provided RNA or cDNA for assay development, target confirmation, panel optimization, and focused expression studies.
A useful expression panel should be built around the scientific hypothesis—not around an arbitrary fixed gene list. IMDNA can support development from target selection through research implementation.
Define the research objective, pathways, candidate genes, transcript context, expected expression range, and available supporting evidence.
Select candidate biomarkers and normalization genes appropriate to the sample type, biological condition, and experimental comparison.
Design assays around appropriate transcript sequences with in-silico specificity review and experimental performance assessment.
Configure compatible targets, reporter channels, concentrations, controls, and reaction conditions while managing multiplex interactions.
Evaluate specificity, amplification behavior, precision, quantitative range, detection behavior, robustness, and multiplex performance as appropriate.
Support SOP/workflow documentation, training, controls, troubleshooting, data-review principles, reagent production, and technology transfer.
Evaluate candidate transcripts and focused signatures emerging from biological hypotheses or discovery datasets.
Investigate transcriptional programs associated with molecular mechanisms without assuming diagnostic specificity.
Compare expression before and after experimental intervention across dose, time, responder, or resistance models.
Study inflammatory, interferon, T-cell, B-cell, myeloid, cytotoxic, regulatory, and other immune-associated programs.
Investigate tumor biology, immune microenvironment, proliferation, apoptosis, stress, hypoxia, resistance, and pathway-associated expression.
Evaluate neuroinflammatory, neuronal-stress, synaptic, mitochondrial, proteostasis, and other investigator-defined transcriptional pathways.
Study cardiac stress, vascular inflammation, endothelial biology, remodeling, fibrosis, oxidative stress, and related expression programs.
Convert broad molecular observations into smaller, reproducible target sets for focused experimental evaluation.
IMDNA provides scientific, technical, assay-development, analytical-evaluation, research-reagent, documentation, manufacturing, and technology-transfer support for gene expression research. Support may include literature-guided target selection, primer/probe development, singleplex and multiplex RT-qPCR optimization, reference-gene evaluation strategies, analytical study design, controls, research workflow documentation, custom reagent preparation, troubleshooting, and transfer support.
Gene expression is highly dependent on biological context and experimental design. IMDNA does not represent that a gene or expression pattern is specific to a disease, predictive of treatment response, prognostic, diagnostic, or clinically actionable unless such a claim has been independently established through the evidence and regulatory pathway appropriate to that specific intended use.
For projects intended for clinical, diagnostic, prognostic, predictive, or regulated use, additional analytical and clinical evidence, quality-system requirements, regulatory review, and other requirements may apply. The responsible product owner, laboratory, sponsor, or research organization determines those requirements and works with the appropriate qualified professionals and authorities.
For Research Use Only (RUO). Not for use in diagnostic procedures.
These sources support the scientific principles used on this page. They do not imply endorsement of IMDNA.
Tell IMDNA about your biological question, pathway, candidate genes, sample type, experimental groups, treatment conditions, timepoints, transcriptomic findings, and desired panel size. Our scientific team can help translate the project into a focused RT-qPCR or multiplex RT-qPCR research workflow with appropriate target-selection, normalization, controls, analytical evaluation, documentation, and technical-transfer considerations.